Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

40.49 -0.15 (-0.37%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news. 
Via Investor's Business Daily
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Roche Holding AG (OTC: RHHBY) has agreed to 
Via Benzinga
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Ignore Crypto: These Stocks Could Make You Rich
Investing in solid, growing businesses is a less risky road to riches than investing in Bitcoin or other cryptocurrencies. 
Via The Motley Fool
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare. 
Via InvestorPlace
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small  
Via Benzinga
Exposures Product Safety
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
The real competitive battle is about to begin, and it will last a long time. 
Via The Motley Fool
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate 
Via Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... 
Via Benzinga
Exposures Product Safety
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
The U.S. 
Via Benzinga
Exposures Product Safety
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
The three companies are spending big on IBD therapies. 
Via The Motley Fool
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
The market's dour reaction to Roivant Sciences' latest deal doesn't add up. 
Via The Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. 
Via InvestorPlace
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
Roche Holding AG (OTC: RHHBY) inked a deal to acquire  
Via Benzinga
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance
The company's third-quarter sales also declined and came in light. 
Via Investor's Business Daily
Exposures COVID-19
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
Roche Holdings AG's (OTC: RHHBY) nine months  
Via Benzinga
Exposures COVID-19
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:  
Via Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing... 
Via Benzinga
Exposures Product Safety
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. 
Via Benzinga
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
Broadcom and Arista lead five stocks sporting a flat base. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
TPST Stock: 7 Things to Know About Tempest Therapeutics
Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock. 
Via InvestorPlace
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
Via Benzinga
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. 
Via InvestorPlace
2 Cathie Wood Stocks That Could Deliver Exponential Returns
These two cutting-edge healthcare companies could be significantly undervalued right now. 
Via The Motley Fool
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.